Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cytovance Biologics, a biopharmaceutical contract manufacturing company, has signed a full service manufacturing collaboration with Selexys Pharmaceutical, a developer of antibody-based therapeutics for inflammatory and thrombotic diseases, for the process development and cGMP manufacture of Selexys's product HPL1 monoclonal antibody.
Subscribe to our email newsletter
The Selexys Pharmaceutical project is to be executed in Cytovance’s multi-product process development and cGMP production facility in Oklahoma City over the next 15 months. The 44,000sqft facility meets the latest international regulatory standards and is custom-designed for efficient and cost-effective production.
The project team will be composed of members of both Oklahoma City-based organizations working closely together.
Scott Rollins, president and CEO of Selexys, said: “Selexys is pleased to announce the selection of Cytovance Biologics as our contract manufacturer for our lead drug candidate for Crohn’s disease. Cytovance brings substantial expertise in biologics manufacturing that will serve to advance our lead drug candidate into clinical development.”